- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00741988
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
Phase II Trial of Ixabepilone and Carboplatin With or Without Bevacizumab in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The trial will include a lead-in phase for each cohort to assess safety. In Cohort A, 10 patients will receive ixabepilone 30 mg/m2 and carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle. If no unexpected toxicities occur, Cohort A will open to enrollment. Enrollment for Cohort A will be done in two stages (after the lead-in portion is completed). The first stage for Cohort A will enroll a total of 22 patients (this will include the 10 patients from the lead-in phase). If there are at least 3 responses during stage 1, enrollment for stage 2 will proceed. For stage 2 of the study, 17 additional patients will be enrolled (for a total of 39 patients in Cohort A). During stage 1 and stage 2, patients in Cohort A will receive treatment with ixabepilone 30 mg/m2 and carboplatin AUC = 6 intravenously (IV) on Day 1 of each 21-day treatment cycle. Treatment will continue until disease progression or unacceptable toxicity occurs.
After the lead-in phase for Cohort A is completed, a similar lead-in portion, also consisting of 10 patients, will be done for Cohort B. Patients in Cohort B will receive ixabepilone 30 mg/m2, carboplatin AUC = 6 intravenously (IV), and bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle. If no unexpected toxicities occur in this group, Cohort B will open to enrollment. Enrollment for Cohort B will also be done in two stages (after the lead-in portion is completed). The first stage for Cohort B will enroll a total of 22 patients (this will include the 10 patients from the lead-in phase). If there are at least 3 responses during stage 1, enrollment for stage 2 will proceed. For stage 2 of the study, 17 additional patients will be enrolled (for a total of 39 patients in Cohort B). During stage 1 and stage 2, patients in Cohort B will receive treatment with ixabepilone 30 mg/m2, carboplatin AUC = 6 intravenously (IV), and bevacizumab 15 mg/kg on Day 1 of each 21-day treatment cycle. Treatment will continue until disease progression or unacceptable toxicity occurs.
Unexpected toxicities include any grade 4 hematologic toxicity or grade 3/4 non hematologic toxicity that does not reverse within 7 days in more than 2 patients.
Eligible patients will receive ixabepilone, carboplatin, and bevacizumab (bevacizumab will be administered to patients in Cohort B only) at 21-day intervals. Patients will be re evaluated every 6 weeks using computerized tomography (CT) scans. Response to therapy will be assigned using Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al. 2000) (see Section 7). Patients who have objective response or stable disease will continue treatment for 6 cycles, until the time of tumor progression or intolerable treatment-related side effects. Patients in Cohort B without progressive disease will be eligible to receive bevacizumab monotherapy for 6 additional cycles, or until undue toxicity or tumor progression occurs.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33901
- Florida Cancer Specialists
-
Gainesville, Florida, Estados Unidos, 32605
- Gainsville Hematology Oncology Associates
-
-
Indiana
-
Terre Haute, Indiana, Estados Unidos, 47802
- Providence Medical Group
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40207
- Consultants in Blood Disorders and Cancer
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20817
- Center For Cancer And Blood Disorders
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Grand Rapids Clinical Oncology Program
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64132
- Research Medical Center
-
-
Montana
-
Great Falls, Montana, Estados Unidos, 59405
- Dr. Donald Berdeaux
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45242
- Oncology Hematology Care
-
-
South Carolina
-
Columbia, South Carolina, Estados Unidos, 29210
- South Carolina Oncology Associates
-
Spartanburg, South Carolina, Estados Unidos, 29303
- Spartanburg Regional Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37023
- Tennessee Oncology, PLLC
-
-
Virginia
-
Newport News, Virginia, Estados Unidos, 23601
- Peninsula Cancer Institute
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histologically confirmed non-small-cell bronchogenic carcinoma (squamous carcinoma, adenocarcinoma, or large cell carcinoma). Cytologic specimens obtained by brushings, washings, or needle aspiration of the defined lesion are acceptable. Mixed tumors with small-cell anaplastic elements are not eligible.
- Patients who have newly diagnosed unresectable stage III or IV disease are eligible. Patients with stage III disease should be ineligible for combined modality therapy
- Patients must not have received any prior antineoplastic chemotherapy for metastatic lung cancer prior to study entry.
- Patients who have had previous radiotherapy as definitive therapy for locally advanced non-small-cell are eligible as long as the recurrence is outside the original radiation port. Radiation therapy must have been completed greater than 4 weeks prior to registration.
- Male or female patients >=18 years of age.
- Life expectancy of at least 3 months.
- ECOG performance status of <=1.
- Measurable disease by RECIST criteria (see Section 7).
Laboratory values as follows:
- ANC >=1500/mm3 (7 days prior to treatment);
- Hemoglobin >=8 g/dL;
- Platelets >=100,000 mm3 (7 days prior to treatment)
- Bilirubin <=1 x ULN for institution
- AST/SGOT <=2.5 x ULN or <=5.0 x ULN in patients with liver metastases and
- ALT/SGPT <=2.5 x ULN or <=5.0 x ULN in patients with liver metastases
- Creatinine <=2.0 mg/dL or
- Calculated (measured) GFR >=40 mL/min
- PT/INR and PTT <=1.5 x ULN
- Peripheral neuropathy <= grade 1.
Exclusion Criteria:
- A history of cardiac disease as defined by malignant hypertension, unstable angina, congestive heart failure of > grade 2 per New York Heart Association (NYHA) criteria (see Appendix B), myocardial infarction within the previous 6 months, or symptomatic cardiac arrhythmias.
- Metastatic brain or meningeal tumors.
- Uncontrolled intercurrent illness.
- Chemotherapy, investigational drug therapy, or major surgery ≤ 4 weeks prior to starting study drug, or patients who have not recovered from side effects of previous therapy.
- Patient is <=5 years free of another primary malignancy, except if the other primary malignancy is not currently clinically significant or requiring active intervention, or if the other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ.
Exclusion Criteria for Enrollment on Bevacizumab (Cohort B):
- Patients with squamous cell histology NSCLC.
- Patients who have had a major surgical procedure (not including mediastinoscopy), open biopsy, or significant traumatic injury within 1 month of beginning bevacizumab.
- Patients who have had primary thoracic radiation within 3 months of beginning bevacizumab.
- Fine needle aspiration, core biopsy, mediastinoscopy or other minor surgical procedure within 7 days of beginning bevacizumab.
- Patients receiving thrombolytic therapy within 10 days of starting bevacizumab.
- Patients with serious non-healing wound, ulcer, or bone fracture.
- Patients with evidence of bleeding diathesis or coagulopathy.
- Patients with history of hemoptysis (defined as bright red blood of ½ teaspoon or more per episode) within 3 months prior to study enrollment.
Patients with proteinuria at screening, as demonstrated by either:
- Urine protein : creatinine (UPC) ratio >=1.0 or
- Urine dipstick for protein >=2+ (patients discovered to have >=2+ proteinuria on dipstick at baseline should undergo a 24-hour urine collection, and must demonstrate <1 g of protein in 24 hours to be eligible).
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Cohort A
ixabepilone 30 mg/m2 and carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
|
ixabepilone 30 mg/m2
Outros nomes:
carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
Outros nomes:
|
Experimental: Cohort B
ixabepilone 30 mg/m2, carboplatin AUC = 6 intravenously (IV), and bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
|
ixabepilone 30 mg/m2
Outros nomes:
carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
Outros nomes:
bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment
Prazo: 18 months
|
The Percentage of Patients Who Experience an Objective Benefit From Treatment
|
18 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Sobrevivência geral (OS), o período de tempo, em meses, que os pacientes permaneceram vivos desde a primeira data do tratamento do protocolo até a morte
Prazo: 18 meses
|
18 meses
|
|
Progression Free Survival, the Length of Time, That Patients Were Alive From Their First Date of Treatment Until Worsening of Their Disease
Prazo: 18 months
|
18 months
|
|
Number of Participants Experiencing Treatment Related Toxicity
Prazo: 18 months
|
Number of participants experiencing Grade 3 and Grade 4 Treatment-related toxicities are reported here.
Toxicities that were occurring >=5% of total patients are listed.
Toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE version 3.0) of the National Cancer Institute.
|
18 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: David R Spigel, MD, Sarah Cannon Research Insititute
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Respiratórias
- Neoplasias
- Doenças pulmonares
- Neoplasias por local
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Carcinoma Broncogênico
- Neoplasias Brônquicas
- Neoplasias Pulmonares
- Carcinoma pulmonar de células não pequenas
- Efeitos Fisiológicos das Drogas
- Agentes Antineoplásicos
- Agentes Antineoplásicos Imunológicos
- Inibidores de angiogênese
- Agentes Moduladores da Angiogênese
- Substâncias de crescimento
- Inibidores de crescimento
- Carboplatina
- Bevacizumabe
Outros números de identificação do estudo
- SCRI LUN 179
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .